Durability: VOQUEZNA demonstrated sustained nocturnal symptom relief throughout the full treatment period, consistent with the 24-hour heartburn relief observed in the full pHalcon-NERD-301 trial.

ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 ...

New York, New York, USA, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Aletheia Capital Endeavours (ACE) today announced the launch of RepIntel, a precision field-intelligence platform designed to close one of ...

Prenetics Global Limited (“Prenetics” or the “Company”), a leading health sciences company, today announced that it has commenced a public offering of shares of its Class A Ordinary Shares (or ...

To access the live webcast for BridgeBio's calls, please visit the “Events and Presentations” page within the Investors section of the BridgeBio website at https://investor.bridgebio.com. A replay of ...

Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company's website at ...

Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (800) 715-9871 (U.S. callers) and (646) 307-1963 (International ...

Title: Identification of CGT1263, a Potent KRAS Inhibitor with Selectivity for Mutant KRAS over HRAS and NRAS Session Date and Time: Poster Session B, Friday, October 24, 2025 – 12:30 p.m. – 4:00 p.m.

For additional information about Picard Medical, please visit or review the Company’s filings with the U.S. Securities and Exchange Commission at Picard Medical, Inc. is the parent company of ...

Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North ...

This 2025 Interim report is available in English and can be downloaded from: The Company's website at www.carbios.com under the “Investors / Regulated information” section, as well as on ...

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved ...